Industry news

The Department of Energy’s National Nuclear Security Administration (NNSA) completed a ten-day nuclear forensics workshop at the Pacific Northwest National Laboratory (PNNL) in Richland, Wash.

the use of magnetic resonance imaging (MRI) in the diagnosis and treatment of prostate cancer indicates a greater than 99 percent rate of cure when combined with high-intensity focused ultrasound (HIFU) treatment.

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) applauds the U.S. Food and Drug Administration (FDA) for its approval of flutemetamol F-18 injection (Vizamyl) for positron emission tomography (PET) imaging of the brain.

PET/MRI is more than adequate in characterizing liver lesions and provides greater lesion conspicuity than PET/CT, offering clinicians a powerful alternative for oncology imaging.

Imaging the inflammatory response with PET could provide more information about traumatic brain injury (TBI) than conventional CT and MRI methods.

What’s bad for your heart is often bad for your brain.

C-11 laniquidar appears to be safe for PET imaging and might prove effective for use as a biomarker for expression of multidrug transporters such as P-glycoprotein in the brain, which could shed light on resistance to central nervous system drugs such as those used to treat epilepsy.

A new review suggests imaging techniques such as PET and SPECT with a variety of tracers can be used to improve the detection of peripheral vascular disease.

Researchers have developed a new approach that uses molecular PET/CT images of patients to create detailed 3D hologram-like displays of human organs for use by surgeons.

Based on its recent analysis of the molecular imaging market, Frost & Sullivan recognizes Siemens Healthcare with the 2013 North American Frost & Sullivan Award for Company of the Year.